ClinicalTrials.gg
RecruitingNCT06284031Updated Feb 28, 2024

Cervical Cancer Brachytherapy With Interstitial Needles in 3 Fractions

An interventional study of 3 fractions HDR brachytherapy in Cervical Cancer, sponsored by National University Hospital, Singapore. Recruiting at 1 site in Singapore. Open to female participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by National University Hospital, Singapore · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Not applicable
Ages
21 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Uterine Cervical Neoplasms with a site in Singapore — 2 open to participants now, 7 under way, 1 of them phase 3. Uterine Cervical Neoplasms · Singapore.

Planned enrollment
13th of 15
56 · median 289
Started
2023
the only one that year
No phase
3 of 18
2 open now
Registered
14th of 18
by date
Lead sponsor
2 of 18
National University Hospital, Singapore

Among the 18 studies in Uterine Cervical Neoplasms with a site in Singapore, this one is the 13th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2023, is one of 3 with no phase, and was the 14th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

2 of the 18 studies in Uterine Cervical Neoplasms with a site in Singapore are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 21 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Uterine Cervical Neoplasms with a site in Singapore, or all of them as a file.
02

Study summary

Aim To determine the feasibility and safety of 3 fractions of high dose rate (HDR) brachytherapy with interstitial needles for cervical cancer in the outpatient setting

Primary objective To determine the clinical outcome (2-yr local control rate, loco-regional control rate, progression free survival and overall survival)

Secondary objective To determine the long-term toxicities of this regimen based on CTCAE v5

Read the detailed description

This study is designed as a single arm phase II prospective study that will be open for recruitment for approximately 3 years. An estimated 56 cervical cancer patients treated in NUH will be recruited.

Pre-treatment Assessment

  1. Case reviewed in gynae multidisciplinary meeting
  2. Detailed gynaecologic assessment on diagnosis
  3. Staging scan - MRI pelvis, CT TAP or PET CT
  4. Baseline blood result - Full blood count, renal panel, liver panel, coagulation profile and Group screen and match

Treatment

All patients will be registered and reviewed in NUH Radiotherapy Centre. Written consent will be obtained if patient is agreeable to be recruited.

Brachytherapy A pre-brachytherapy planning magnetic resonance imaging (MRI) scan is performed to evaluate the response and extent of the parametrial involvement if any, as well as to determine the ideal placement of interstitial needles to achieve optimal coverage. The applicator to be used should be chosen prior to BT if possible. Twenty-four hours prior to the procedure, oral fleet is given to the patient to ensure adequate bowel preparation.

The 3 fractions of HDR brachytherapy may be delivered in the following ways:

Option 1: 3 insertions over 2 non-consecutive days:

9 Gy to the HRCTV in the first fraction on day 1 of the brachytherapy procedure and 7 Gy x 2 fractions at least 6 hours apart on day 2, retaining the same brachytherapy applicators of the second insertion for the final fraction.

Option 2: 3 insertions over 3 non-consecutive days 8Gy to the HRCTV per fraction per day for 3 non-consecutive days. Acute and late radiation toxicities will be scored according to Common Terminology Criteria for Adverse Events (CTCAE), version 5 Patients will be followed up at 1 month with a physical examination and with an MRI of the cervix within 3 months post procedure.

Patients will subsequently be followed up every 3 monthly with vaginal examination for the next 2 years. At each follow-up, toxicity will be recorded as per the CTCAE.

03

Conditions studied

  • Cervical Cancer
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 21 years old and above
  2. proven squamous cell carcinoma, adenocarcinoma, adenosquamous or poorly differentiated cervical cancer
  3. Clinically or radiologically stage IB - IVA cervical cancer based on TNM 8th Edition
  4. performance status 0, 1, or 2
  5. To complete external beam radiotherapy and brachytherapy in NUH
  6. Written, voluntary
  7. Patients must be accessible for follow up and management in NUH

Exclusion criteria

Exclusion Criteria:

  1. Post operative cervical cancer cases
  2. Pregnant or breastfeeding women
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    3 fractions

    Procedure: 3 fractions HDR brachytherapy

Interventions

  • Procedure3 fractions HDR brachytherapy

    The 3 fractions of HDR brachytherapy may be delivered in the following ways: Option 1: 3 insertions over 2 non-consecutive days: Option 2: 3 insertions over 3 non-consecutive days

06

What researchers measure

Primary outcomes

  1. Local control rate

    Percentage of patients who recurred at the site of the initial primary (the cervix).

    Time frame: 2 years from time of recruitment

  2. Loco-regional control rate

    Percentage of patients who recurred in the pelvis or regional lymph nodes (not in cervix).

    Time frame: 2 years from time of recruitment

  3. Progression-free survival (PFS)

    Percentage of patients who develop first evidence of cancer recurrence.

    Time frame: 2 years from time of recruitment

  4. Overall survival (OS)

    Percentage of patients who died from any cause

    Time frame: 2 years from time of recruitment

Secondary outcomes

  1. Long term toxicities

    To determine the long-term toxicities of this regimen based on CTCAE v5

    Time frame: 2 years from time of recruitment

07

Study locations

1 of 1 sites recruiting
  • National University Hospital
    Singapore, 119074, Singapore
    Recruiting
    • Fatin Aliyah, BSc · Contactfatin_hussin@nuhs.edu.sg · +6581005851
    • Syadwa Abdul Shukor, MD · Sub investigator
    • Yiat Horng Leong, MD · Sub investigator
    • Shing Fung Lee, MD · Sub investigator
    • Michelle Tseng, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jun 2026, 36 months after the start.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 36 months is close to that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2023
First posted
Feb 28, 2024
StartActual
Jun 26, 2023
Primary completionEst.
Jun 2026
CompletionEst.
Dec 2026
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06284031
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
Jun 26, 2023
Primary completion
Jun 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 28, 2024

Study contacts

Fatin Aliyah, BSc
Contact
fatin_hussin@nuhs.edu.sg
+6581005851
Vicky Koh, MD
principal investigator · National University Hospital, Singapore

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion